ALX Oncology (NASDAQ:ALXO – Get Free Report) and Medicus Pharma (NASDAQ:MDCX – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, dividends, risk and institutional ownership.
Analyst Recommendations
This is a summary of current ratings for ALX Oncology and Medicus Pharma, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ALX Oncology | 1 | 0 | 5 | 0 | 2.67 |
| Medicus Pharma | 1 | 1 | 2 | 0 | 2.25 |
ALX Oncology presently has a consensus target price of $4.60, suggesting a potential upside of 158.43%. Medicus Pharma has a consensus target price of $9.00, suggesting a potential upside of 2,592.19%. Given Medicus Pharma’s higher probable upside, analysts clearly believe Medicus Pharma is more favorable than ALX Oncology.
Insider and Institutional Ownership
Risk and Volatility
ALX Oncology has a beta of 0.44, meaning that its share price is 56% less volatile than the S&P 500. Comparatively, Medicus Pharma has a beta of 0.14, meaning that its share price is 86% less volatile than the S&P 500.
Profitability
This table compares ALX Oncology and Medicus Pharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ALX Oncology | N/A | -124.06% | -85.57% |
| Medicus Pharma | N/A | -3,137.84% | -311.33% |
Valuation and Earnings
This table compares ALX Oncology and Medicus Pharma”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ALX Oncology | N/A | N/A | -$101.69 million | ($1.49) | -1.19 |
| Medicus Pharma | N/A | N/A | -$35.46 million | ($2.68) | -0.12 |
ALX Oncology is trading at a lower price-to-earnings ratio than Medicus Pharma, indicating that it is currently the more affordable of the two stocks.
Summary
ALX Oncology beats Medicus Pharma on 8 of the 11 factors compared between the two stocks.
About ALX Oncology
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
About Medicus Pharma
Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.
Receive News & Ratings for ALX Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ALX Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
